In the 7 th edition of the AJCC staging system, the mitotic rate criterion replaced Clark level to increase correct classification of high-risk thin melanoma patients (pT1B). Additionally, sentinel node biopsy (SNB) was recommended for nodal staging of pT1B melanomas. The aim of this article was to evaluate the effects on pT1 substaging and clinical implications in the national pT1 melanoma population. (2) 2010-2014 (7 th ). Relative survival was calculated to estimate melanoma-specific survival. A total of 29.546 pT1 melanoma patients were included. The pT1b proportion increased from 10.1% in Cohort 1 to 21.5% in Cohort 2. The proportion of performed SNBs per cohort increased: for pT1b melanomas alone from 4.5% to 13.0%. SNB positivity rate decreased from 10.5% to 8.8% for the entire pT1 population, and for pT1b melanomas from 11.3% to 8.6%. At 5 years, the relative survival rate was similar for pT1a and pT1b in both cohorts, namely, pT1a 100% vs pT1b 97% (Cohort 1), and pT1a 100% vs pT1b 98% (Cohort 2). The 7 th edition of the AJCC staging system has caused an increased number of patients to undergo SNB, without an increase in SNB positivity rate. Survival between pT1 subgroups remains similar. The mitotic rate criterion for pT1b classification and the recommendation to perform SNB for pT1b melanomas should be reconsidered.
The incidence of newly diagnosed cutaneous melanomas continues to increase globally and in the Netherlands. 1, 2 The majority of all new melanoma patients have a thin melanoma (pT1, Breslow thickness 1.00 mm), which has a good prognosis (10-year survival is 92-95%). [3] [4] [5] A minority of these patients, however, will develop regional and distant metastases, and ultimately die due to melanoma.
One of the most important prognostic factors for primary melanomas is the Breslow thickness, which has become the main allocator for the different primary tumor (pT) categories. 3, 6, 7 In the 6 th edition of the American Joint Committee on Cancer (AJCC) Staging System, the presence of ulceration was major criterion for pT1b classification besides a high Clark level (4/5) , and recommendations for Sentinel Node Biopsy (SNB) were based on classification as pT1b melanoma. 8, 9 In the 7 th edition of the AJCC Staging System, high Clark level was replaced by mitotic rate; that is, the microscopic presence of 1 or more mitotic cells per 1 mm 2 . This was found to be a stronger prognostic factor than high Clark level. 3, 10 The extent of its power in thin melanomas is, however, debated; the cutoff point of 1 or more mitosis per mm 2 may be too low to be used as discriminating prognostic feature, and the large variety in histopathological examination protocols (number of examined slides, number of searched high power fields, size of high power fields) make it highly operator dependent. 11 Importantly, the decision to perform further nodal staging with an SNB in pT1 melanomas is based on this criterion in the Dutch melanoma guidelines. 4 An SNB is a minimally invasive surgical staging procedure, but an invasive procedure nonetheless. 12, 13 Changes in melanoma classification due to the update from 6 th to 7 th edition may have a large effect on the absolute number of patients that will be offered an SNB. This will also affect the absolute number of patients at risk for morbidity due to the fact that the incidence of pT1 melanomas is high compared to pT2-4 melanomas.
Besides the question if an SNB is warranted in thin melanomas, it is not known if the mitotic rate criterion stratifies thin melanomas more accurately as high-risk patients in the Dutch population. A corresponding higher risk of a positive SNB would be expected.
Aim of this study is to evaluate the effects of implementation of the 7 th edition of the AJCC staging system and subsequent change to the national guidelines on pT1 substaging and clinical implications in the national pT1 melanoma population.
Patients and Methods

Patients
Population-based data was retrieved for all pT1 melanoma patients diagnosed between 2003 and 2014 from the Netherlands Cancer Registry (NCR), which is embedded within the Netherlands Comprehensive Cancer Organisation. 2 The NCR is annually linked to the Municipal Personal Records database to retrieve information on vital status and date of death. The follow-up data were completed until January 1, 2015.
The following patient and melanoma features were collected: gender, age at diagnosis, year of diagnosis, Breslow thickness, pT classification, stage, SNB performed yes/no, SNB result, whether completion lymph node dissection was performed (CLND), CLND result, number of removed lymph nodes, number of removed positive lymph nodes, follow-up from date of diagnosis in months, and status at last followup (dead or alive).
Patients were divided into two cohorts based on the year of diagnosis and use of the AJCC Staging System 6th edition, Cohort 1 (2003 Cohort 1 ( -2009 Because, the registration methods used during Cohort 1 data on SNB were not accurate for this cohort. In case of a positive SN, CLND data sometimes overruled the SN data. This way, it was not possible to distinguish between patients with a lymph node dissection (LND) following a positive SN or with clinically involved lymph nodes warranting therapeutic LND. The registration methods for SNB were adapted prior to 2010 with the option to register SN data separately from LND data: SNB data for Cohort 2 thus were accurate. A quality control on accuracy of tumor staging has been performed for the entire database in 2016 prior to selection of data.
Statistics
Primary patient and tumor features were analyzed using X 2 -tests or Mann-Whitney U test, as appropriate. The proportion of pT1a and pT1b was determined per cohort and per year of diagnosis. Incidence-rates were standardized for age according to the world standard population (WSR, World Standardized Rate) and are presented per 100,000 personyears. The proportion of performed SNBs was determined per cohort and per pT1 category, as well as the proportion of positive SNs. Follow-up was calculated from the date of diagnosis until last follow-up or death. Survival times were calculated from the melanoma diagnosis to death (any cause) and considered censored for patients alive at last follow-up. Cause of death was not known.
Survival time was defined as time from diagnosis to death, or January 1, 2015 for those patients who were still alive. Relative survival was used as proxy of disease-specific survival and was calculated correcting for age-and gender-specific background mortality. 14 
Results
Patients
A total of 29.546 pT1 melanoma patients were registered for the time period 2003-2014. Of these patients, 23,879 (80.8%) were classified as pT1a, 4,779 (16.2%) as pT1b, and 888 (3.0%) were not further classified due to missing data on either Clark level or mitotic rate of the presence of ulceration at the time of registration. See Table 1 for patient and melanoma features. Breslow thickness was comparable between Cohort 1 and 2 (median 0.60 and 0.58), although statistically significant (p < 0.001), probably due to the large number of patients in the study population. In Cohort 2, more patients were of the male sex and median age was higher (Table 1 ).
What's new?
Generally considered low-risk, thin melanoma (pT1) has been associated with increasing numbers of deaths in recent years. Accordingly, the American Joint Committee on Cancer (AJCC) updated its staging criteria, replacing assessments of tumor skin penetration with evaluation of mitotic rate and the option for sentinel node biopsy (SNB) for high-risk (pT1b) melanomas. This Dutch population-based analysis shows, however, that while implementation of the updated staging system doubled pT1b incidence in the Netherlands, it also doubled the number of SNBs, with no improvements in survival. Mitotic rate alone may not be a viable path to improving high-risk pT1b patient identification.
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Median follow-up for Cohort 1 was 92 months [IQR 72-115 months]; median follow-up for Cohort 2 was 28 months [IQR 14-43 months]. The incidence of thin melanomas increased over the investigated time period, starting at 1503 new pT1 melanomas in 2003 (pT1a 2.6/100,000 person-years and pT1b 0.3 100,000 person-years (WSR)), up to 3430 new pT1 melanomas in 2014 (pT1a 4.9/100,000 person-years and pT1b 1.5/100,000 person-years (WSR)) (Supporting Information, Fig. S1 ).
pT1b classification
The pT1b proportion differed significantly between both entire cohorts: 10.1% in Cohort 1 vs 21.5% in Cohort 2 (p < 0.0001). There was a clear increase in the pT1b proportion from 2011 onward (Fig. 1) .
Sentinel node biopsies
The proportion of pT1 patients undergoing SNB doubled over time: 2.0% in Cohort 1 vs 4.8% in Cohort 2 (p < 0.0001) (Fig. 2 ). The proportion of pT1b patients undergoing SNB increased almost threefold in Cohort 2 (Fig. 2) . The proportion of patients with a positive SN was comparable in both cohorts (10.6% vs 9.0% without patients with unknown results, p 5 0.445) ( Table 2 ). Of all positive SN patients, 46% (n 5 44) underwent a CLND (20 (69%) in cohort 1 and 24 (36%) in cohort 2). The proportion and number of positive non-SNs was unknown as this was registered combined with the number of positive SNs in the NCR. Previous AJCC staging systems and others report a cutoff at 0.75 mm Breslow. To analyze this point, we have used this distribution in both cohorts with the current pT1a and pT1b: 0.75 mm and 0.76-1.00 mm without/with mitoses ( Table 2) .
Survival
At 5 years, the relative survival rate was similar for pT1a and pT1b in both cohorts, namely, pT1a 100% (standard error (SE) 0.2%) vs 100% (SE 0.5%) and pT1b 97% (SE 0.8%) vs 98% (SE 1.2%) (Fig. 3) . The small group of unspecified pT1 patients had survival rates comparable with pT1a (data not shown). Five-year relative survival rate for pT1a patients with/without SNB was both 100% (Cohort 1) and 96% vs 100% (Cohort 2); 5-year relative survival for pT1b patients with/without SNB was both 97% (Cohort 1) and 97% vs 98% (Cohort 2).
Five-year relative survival rate per SN status was 100% (SE 1.3%) vs 88% (SE 6.5%) for SN negative vs SN-positive patients in Cohort 1. In Cohort 2, only 4-year relative survival rate could be calculated due to a low number of cases: this was 99% (SE 1.4%) for SN-negative patients vs 85% (SE 8.2%) for SN-positive patients. Relative survival for Breslow 0.75 mm and >0.75 mm was calculated for pT1a and pT1b, stratified per cohort (Fig. 4) .
Discussion
An increasing incidence of melanoma has been seen in the Netherlands already during many recent years. 1, 15 In this report, we continue to see this increasing incidence of melanoma and see an increasing incidence of thin melanomas over the investigated time period (Supporting Information, Fig. S1 ) too. The proportion of pT1b patients increased considerably from 2011. One year later (in 2012), the new version of the Dutch Melanoma Guideline was finalized, including the recommendation to consider SNB for pT1b melanoma and higher (previously for T2 melanoma and higher). 4 The Dutch Cancer Registry started using the 7th 
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edition of the AJCC staging system since 2010, but not all hospitals updated their staging system or clinical practice immediately, causing a temporary delay in the new classification of pT1b primaries according to the 7 th AJCC edition. The increased proportion of performed SNBs for pT1 patients (from 2% to 4.8%) was mainly caused by a steep increase in SNBs performed for pT1b patients in Cohort 2. This could be expected considering the recommendation to offer SNB (but not mandatory to perform) for pT1b patients in the updated Dutch Melanoma Guideline in 2012.
When taking into account that after 2012 all pT1b patients should be offered an SNB according to the updated guidelines, the proportion of performed SNBs in the second cohort (13.0%) is still relatively low compared to the proportion of performed SNBs for intermediate thickness melanomas (pT1b-T3b): this was approximately 40% between 2003 and 2011. 5 Again for intermediate thickness melanomas, the guidelines recommend to offer an SNB, but it is not mandatory to perform an SNB. A significant increase in the actual number of patients being exposed to SNB surgery can be observed (from 62 to 443 pT1b patients). As pT1 melanomas form the majority of all newly diagnosed melanomas, this has clear clinical implications: a more stressed referral system, increased wait lists, and increased costs. Let alone the increased number of patients being exposed to potential, albeit low, chance of morbidity related to the SNB, and CLND in case of a positive SN.
The actual number of patients with a negative SNB increased from 245 to 677. If all the potential pT1b patients would undergo an SNB, the number of additional SNB procedures would increase with 2,955 nationwide (fourfold increase for all pT1 melanomas). This would have massive budget implications to the national health care system, but more importantly, the potential absolute number of patients at risk for unnecessary morbidity (approximately 300 individuals).
An interesting finding was that CLND was performed less often in Cohort 2, which did not result in a decreased survival. This is in line with the results of the MSLT-1 and DeCOG trials, showing no survival difference for patients with immediate or delayed CLND. 16, 17 Previous AJCC staging systems and others report a cutoff at 0.75 mm Breslow to offer patients an SNB. 18, 19 In Cohort 2, SNB positivity rate for pT1a 0.75 mm and 0.76-1.00 mm was 5.7% vs 10.0% (p 5 0.357), and for pT1b, 7.4% vs 9.4% (p 5 0.572) ( Table 2 ). Although not significant in this series, SN positivity rate was higher for melanomas with a Breslow thickness of >0.75 mm in both pT1a and pT1b patients. SN positivity rate appears to be mainly driven by Breslow thickness and not by mitotic rate as it is currently defined.
Relative survival was excellent for the Dutch population. An increase in survival difference between pT1 substages was not observed, indicating that the stratification of high-risk patients did not improve. Summarizing, our data show an increase in the proportion of pT1b melanomas and a parallel increase in the proportion of performed SNBs in pT1b melanomas, but no increase in the proportion of positive SNs or a clear worse prognosis for all pT1b melanomas in the second cohort (7 th edition AJCC). This implies that there has been stage migration between pT1a and pT1b, more specifically, patients formerly classified as pT1a now being classified as pT1b solely on presence of at least 1 singly mitosis/mm 2 . In a Surveillance, Epidemiology, and End Results (SEER) cancer registry study, the proportion of pT1b melanomas increased from 16.1% to 22.4%, but the proportion of performed SNBs for pT1b melanomas decreased (from 40.9% to 33.3%), and no significant increase in the proportion SN positive pT1b patients (7.1% vs 8.5%) was found. 20 As they only compared the year 2010 (7 th edition) with 2004-2009 (6 th edition), any changes due to the implementation of the 7 th edition after 2010 are not included in their analyses, which is a drawback of that study.
On top of the increase of diagnosed pT1b melanomas due to the mitotic rate criterion, the recommendation to perform nodal staging with an SNB in these patients may have driven some pathologists to perform an active search for mitoses (possibly even make and examine additional slides) to be able to diagnose a melanoma as pT1b, leading to overdiagnosis. This will further trouble the identification of true highrisk patients. Also, this will diminish the potential benefits of nodal staging for pT1b melanoma patients, which may not weigh up against the costs of SNB surgery.
Several studies have reported on the prognostic value of mitotic rate in thin melanomas, [21] [22] [23] [24] which formed the basis of including this in the 7th edition of the AJCC staging system.
3,10 Kirkland et al. queried the mitotic rate criterion of the 7 th AJCC staging edition considering the fact that it is associated with the decision to offer an SNB. 11 They conclude in their review that despite its statistically significant value as prognostic variable, the chosen cutoff of 1 mitosis/mm 2 does not have a clear clinically relevant impact on survival rates (nor on SN positivity rates), and thus does not warrant the decision to perform SNB in these patients in a routine fashion. This is supported by Wat et al. who found no association between mitotic rate and SN status in pT1 melanomas, 25 and by Speijers et al. who also could not confirm a relationship between mitotic rate and SN status, nor for mitotic rate and survival. 26 Due to the fact that the data used are derived from a national registry system, available data are restricted to the registration performed at the time of diagnosis. Unfortunately not all data on SNBs performed in cohort 1 are available, as explained in the methods section. Potentially, there may have been more patients who underwent an SNB which is registered as an LND only.
The actual details for pT1 substaging were not available for this study (i.e., mitotic rate, Clark level, and ulceration), but all T staging was based on these criteria according to the AJCC staging system valid at the time of diagnosis.
In Cohort 2, the male gender was over-represented, and the median age was higher. This may have biased results, but these features were adjusted for in survival analyses to minimize potential bias.
The cause of death is unknown for all patients because the registry data are anonymized after initial registry. However, we used a method to calculate relative survival adjusting for tumor-and patient-specific features, which forms an adequate alternative for disease-specific survival.
Despite these drawbacks, data are present from all melanomas diagnosed between 2003 and 2014 on a national level, including not only primary tumor data but also SN and LND data, and mature follow-up data. This provides valuable insight in incidence and prognosis of pT1 melanomas from the entire Dutch population.
Conclusions
pT1 incidence has increased in the Netherlands over the past decade. Introduction of the mitotic rate criterion for pT1b substaging and the recommendation to perform SNB for pT1b melanoma has led to a proportional increase in pT1b melanomas, and an increase in performed SNBs. SN positivity rate has not increased and survival remained stable for pT1b melanomas, indicating that mitotic rate alone as criterion for pT1b has not improved selection of high-risk pT1 patients for optional further (nodal) staging.
Based on the results of this study and considering the fact that survival of Cohort 2 was not different at 5-year followup, recommendation on SNB for pT1b melanomas may be reconsidered as well.
